

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Proposed Single Technology Appraisal

Ofatumumab for treating relapsing multiple sclerosis ID1677

Provisional stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u> Novartis (ofatumumab)</p> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Brain and Spine Foundation • MS-UK • Multiple Sclerosis National Therapy Centres • Multiple Sclerosis Society • Multiple Sclerosis Trust • Muslim Council of Britain • Neurological Alliance • Shift.ms • South Asian Health Foundation • Specialised Healthcare Alliance • Sue Ryder • Brain Charity <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of British Neurologists • British Association of Neuroscience Nurses • British Geriatrics Society • British Neuropathological Society • British Society of Rehabilitation Medicine • Chartered Society of Physiotherapy • Institute of Neurology • Primary Care and Community Neurology Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Occupational Therapists • Royal College of Pathologists 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • Multiple Sclerosis Society Wales • National Association of Primary Care • National Pharmacy Association • Neurological Alliance of Scotland • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Wales Neurological Alliance • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Bayer (interferon beta-1b) • Biogen Idec (dimethyl fumarate, interferon beta-1a, natalizumab, peginterferon beta-1a) • Celgene (ozanimod) • Merck (interferon beta-1a, cladribine) • Mylan (glatiramer acetate) • Novartis (interferon beta-1b, fingolimod, siponimod)

Provisional stakeholder list for the proposed technology appraisal of ofatumumab for treating relapsing multiple sclerosis ID1677

Issue date: November 2019

© National Institute for Health and Care Excellence 2019. All rights reserved

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Therapists in MS (TIMS) • UK Clinical Pharmacy Association • UK Multiple Sclerosis Specialist Nurse Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS Rotherham CCG • NHS Surrey Downs CCG • NHS England • Welsh Government 	<ul style="list-style-type: none"> • Roche (ocrelizumab) • Sanofi Genzyme (alemtuzumab, teriflunomide) • Teva UK (glatiramer acetate) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Brain Research UK • British Neurological Research Trust • Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTees AND COMMENTATORS

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.